Stay updated on Nintedanib vs Placebo in Scleroderma Lung Fibrosis Clinical Trial

Sign up to get notified when there's something new on the Nintedanib vs Placebo in Scleroderma Lung Fibrosis Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Nintedanib vs Placebo in Scleroderma Lung Fibrosis Clinical Trial page

  1. Check
    4 days ago
    Change Detected
    Summary
    No new or removed content on the Study Details page for NCT02597933. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.1%
    Check dated 2025-11-03T13:44:20.000Z thumbnail image
  2. Check
    11 days ago
    No Change Detected
  3. Check
    32 days ago
    Change Detected
    Summary
    - Added a government-operating-status notice and a link to official sources; updated to v3.2.0. - Removed a specific resource on Systemic sclerosis and old version tag v3.1.0.
    Difference
    2%
    Check dated 2025-10-06T04:23:20.000Z thumbnail image
  4. Check
    39 days ago
    Change Detected
    Summary
    Added a new 2025 Scleroderma lung disease article citation and updated version to v3.1.0; removed an older ahead-of-print citation and several drug-safety category tags (likely a cleanup of categories).
    Difference
    0.4%
    Check dated 2025-09-28T23:41:07.000Z thumbnail image
  5. Check
    54 days ago
    Change Detected
    Summary
    Version bump from v3.0.1 to v3.0.2; no substantive content changes detected. The removal of 'Back to Top' is a minor UI change.
    Difference
    0.1%
    Check dated 2025-09-14T10:01:14.000Z thumbnail image
  6. Check
    61 days ago
    Change Detected
    Summary
    The web page has been updated from version 3.0.0 to 3.0.1, indicating a revision in the content. There are no significant changes to core content or other important elements.
    Difference
    0.1%
    Check dated 2025-09-07T07:55:53.000Z thumbnail image
  7. Check
    68 days ago
    Change Detected
    Summary
    The webpage has undergone significant updates, including the addition of new facility names and locations, as well as important references to drug safety and systemic sclerosis research. Notably, the term 'nintedanib' has been retained, while previous mentions of 'nintedanib esylate' and 'Scleroderma, Diffuse' have been removed.
    Difference
    7%
    Check dated 2025-08-31T01:02:20.000Z thumbnail image

Stay in the know with updates to Nintedanib vs Placebo in Scleroderma Lung Fibrosis Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Nintedanib vs Placebo in Scleroderma Lung Fibrosis Clinical Trial page.